News
RHHVF
240.00
NaN%
--
Weekly Report: what happened at RHHVF last week (0429-0503)?
Weekly Report · 1d ago
UBS Sticks to Their Hold Rating for Roche Holding AG (RHHVF)
TipRanks · 1d ago
UPDATE 3-Regeneron's blockbuster eye drug posts weaker sales due to inventory impact
Regeneron's blockbuster eye drug posts weaker sales due to inventory impact. Total sales of the drug Eylea fell 2% to $1.40 billion in the January-to-March quarter. Higher dose version of drug, however, beat consensus estimates. U.S. Drugmaker misses Wall Street estimates for quarterly profit.
Reuters · 5d ago
UPDATE 2-Regeneron misses profit estimates on weaker Eylea and Dupixent sales
Regeneron misses profit estimates on weaker Eylea and Dupixent sales. Company reported adjusted profit of $9.55 per share for first quarter. Sales of blockbuster eye drug fell 2% to $1.40 billion in the January-to-March quarter.
Reuters · 5d ago
UPDATE 3-Bird flu testing shows more dairy products are safe, US FDA says
U.S. FDA says bird flu testing shows more dairy products are safe. Tests on sour cream and cottage cheese show pasteurization inactivates the bird flu virus, agency says. The agency has confirmed bird flu in 36 dairy herds in states since March. The USDA believes the virus is spreading through contact with raw milk.
Reuters · 5d ago
Weekly Report: what happened at RHHVF last week (0422-0426)?
Weekly Report · 04/29 10:17
Roche: Value Remains Despite Covid-19 Revenue Growth Loss
Roche has good long-term prospects despite Covid-19 revenue growth loss. Vabysmo and Phesgo are still strong growth drivers for the company going forward. Ocrevus is expected to remain as the best-selling Multiple Sclerosis Drug in 2030. The company has established a huge acquisition for drugs for the obesity drugs market.
Seeking Alpha · 04/28 09:44
AbbVie's Q1: Positive Surprise
Seeking Alpha · 04/26 16:01
These Are The Biotechs Showing Up At The Biggest Cancer Meeting Of The Year (Oral Presentations)
Annual Meeting of the American Society of Clinical Oncology will be held in Chicago. The oral presentations will cover a range of topics including targeted therapies and immunologic therapies for various types of cancer. The plenary session will feature presentations on esophageal cancer, melanoma and lung cancer.
Seeking Alpha · 04/25 21:49
Scholz promises support for pharma sector in Germany as Merck invests
German Chancellor Olaf Scholz promises support for pharma sector in Germany as Merck invests. Merck is investing 1.5 billion euros in Germany. The drugmaker plans to use its life sciences Advanced Research Centre in Darmstadt. Germany has sought to improve conditions for the pharma and biotech sector.
Reuters · 04/25 10:11
DZ BANK AG Sticks to Its Buy Rating for Roche Holding AG (RHHVF)
TipRanks · 04/24 16:25
GLOBAL MARKETS-Shares jump on tech boost; fragile yen on intervention watch
World stocks rise on Wednesday led by gains in the tech sector. Japan's yen touches 34-year low against the dollar and is on intervention watch. After-hours surge in shares of Tesla lifts sentiment in Asia and Europe. The euro rises to its highest in more than a week after strong euro zone PMIs.
Reuters · 04/24 15:04
Artisan International Fund Q1 2024 Commentary
Seeking Alpha · 04/24 14:00
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Day One Biopharmaceuticals (DAWN) and Roche Holding AG (OtherRHHVF)
TipRanks · 04/24 11:50
UPDATE 1-Biogen beats quarterly profit estimates, Alzheimer's drug sales jump
Biogen beats quarterly profit estimates, Alzheimer's drug sales jump. The company's shares up 4% before the bell. Biogen has cut jobs and abandoned controversial drug Aduhelm to boost growth. Company says its new drug Leqembi recorded global sales of about $19 million.
Reuters · 04/24 11:30
UBS Remains a Hold on Roche Holding AG (RHHVF)
TipRanks · 04/24 11:05
UPDATE 2-STOXX 600 falls on banks drag; tech contains losses on ASMI boost
STOXX 600 index closes 0.5% lower after initially rising to its highest in over a week. Financials drag after Swedish lender Handelsbanken posts disappointing earnings. Tech stocks contain losses on ASM International's strong forecast, but tech stocks rise 1.3% on ASMI boost.
Reuters · 04/24 09:18
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), Danaher (DHR) and Roche Holding AG (OtherRHHVF)
TipRanks · 04/24 08:50
Wall Street Analysts Are Neutral on Top Healthcare Picks
TipRanks · 04/24 08:20
LIVE MARKETS-Europe eyes higher start as earnings kick into high gear
Europe eyes higher start as earnings kick into high gear. FTSE 100 futures point to another positive day for European stocks. Tesla kicks off the earnings cycle for U.S. Technology heavyweights. Luxury stocks in Europe come into focus after Kering forecast a 40-45% plunge in H1 operating profit.
Reuters · 04/24 06:47
More
Webull provides a variety of real-time RHHVF stock news. You can receive the latest news about Roche Hldg through multiple platforms. This information may help you make smarter investment decisions.
About RHHVF
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.